Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica MacIntyre

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Cancer|February 2, 2012
A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumorsCaio M Rocha-Lima, Soley Bayraktar, Jessica Macintyre, et al.
American Journal of Clinical Oncology|February 7, 2012
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancerPeter J Hosein, Gilberto de Lima Lopes, Vitor H Pastorini, et al.
JAMA Network Open|June 21, 2023
Factors Associated With Unmet Supportive Care Needs and Emergency Department Visits and Hospitalizations in Ambulatory OncologyFrank J Penedo, Akina Natori, Sara E Fleszar-Pavlovic, et al.
Cancer Investigation|October 16, 2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancerCaio M Rocha Lima, Soley Bayraktar, Aurea M Flores, et al.
BMC Cancer|May 31, 2012
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinomaPeter J Hosein, Jessica Macintyre, Carolina Kawamura, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 29, 2015
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinomaMoh'd Khushman, Naomi Dempsey, Jennifer Cudris Maldonado, et al.
Academic Pathology|October 22, 2020
A How-to Guide to Building a Robust SARS-CoV-2 Testing Program at a University-Based Health SystemStephen D Nimer, Jennifer Chapman, Lisa Reidy, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Cancer|February 2, 2012
A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumorsCaio M Rocha-Lima, Soley Bayraktar, Jessica Macintyre, et al.
American Journal of Clinical Oncology|February 7, 2012
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancerPeter J Hosein, Gilberto de Lima Lopes, Vitor H Pastorini, et al.
JAMA Network Open|June 21, 2023
Factors Associated With Unmet Supportive Care Needs and Emergency Department Visits and Hospitalizations in Ambulatory OncologyFrank J Penedo, Akina Natori, Sara E Fleszar-Pavlovic, et al.
Cancer Investigation|October 16, 2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancerCaio M Rocha Lima, Soley Bayraktar, Aurea M Flores, et al.
BMC Cancer|May 31, 2012
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinomaPeter J Hosein, Jessica Macintyre, Carolina Kawamura, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 29, 2015
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinomaMoh'd Khushman, Naomi Dempsey, Jennifer Cudris Maldonado, et al.
Academic Pathology|October 22, 2020
A How-to Guide to Building a Robust SARS-CoV-2 Testing Program at a University-Based Health SystemStephen D Nimer, Jennifer Chapman, Lisa Reidy, et al.
Pageof 3